Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Uterine (endometrial) cancer
E7386 (β-catenin–CBP inhibitor) + lenvatinib delivers 36.7% ORR in post–chemo/PD-(L)1 advanced endometrial cancer
E7386 is an oral inhibitor of the beta-catenin/CBP interaction, combined with the multikinase VEGFR/FGFR inhibitor lenvatinib in the global Phase 1b/2 Study 102 dose-expansion cohort (NCT04008797). All 30 patients…
NCT04008797 - Trial result
Pancreatic cancer
Motixafortide (CXCR4 inhibitor) + cemiplimab (PD-1) + gem/nab-paclitaxel posts 55% confirmed ORR in 1L metastatic PDAC
Motixafortide is a CXCR4 antagonist intended to disrupt the CXCR4/CXCL12-driven immune-excluded PDAC microenvironment, paired here with the PD-1 antibody cemiplimab plus gemcitabine/nab-paclitaxel (MCGN). In an…
NCT04543071 - Trial result
Pancreatic cancer
ACT (PS101 + focused ultrasound) plus mFOLFIRINOX shows early responses and a resection conversion signal in locally advanced/borderline PDAC
Acoustic Cluster Therapy (ACT) is an investigational ultrasound-mediated drug delivery approach in which IV PS101 (perfluorocarbon microbubbles/microdroplets) is activated by focused ultrasound to transiently…
NCT06850623 - Trial result
Pancreatic cancer
Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer
Atebimetinib is a MEK inhibitor developed to pair direct anti-tumor activity with mitigation of cancer cachexia/body-mass loss, and was evaluated with modified gemcitabine/nab-paclitaxel (mGnP) in first-line…
NCT07562152 - Trial result Spotlight
Brain and CNS tumors
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets
Cesium-131 collagen tile-based radiation therapy (TBRT; intraoperative brachytherapy that delivers focal radiation immediately after resection) was compared with standard post-operative stereotactic radiation therapy…
NCT04365374 - Trial result
Brain and CNS tumors
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint
Lanreotide depot/autogel is a long-acting somatostatin analog that targets somatostatin receptors (SSTRs) expressed on many pheochromocytomas/paragangliomas (PPGLs). In results reported as a medRxiv preprint, the…
NCT03946527 - Trial result
Multiple solid tumors
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors
Tovorafenib is an oral, selective, CNS-penetrant type II inhibitor of BRAF and CRAF evaluated as monotherapy in the Phase II FIRELIGHT-1 DAY101-102a substudy (NCT04985604) in recurrent/refractory solid tumors with…
NCT04985604 - New trial
Non-small cell lung cancer
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC
This Phase 1, single-arm Georgetown University study tests whether five-fraction stereotactic body radiation therapy (SBRT) delivered on the Accuray CyberKnife system can safely control ultra-central, node-negative…
NCT07852247 Exploratory - New trial
Non-small cell lung cancer
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC
Chugai Pharmaceutical is running this first-in-human, open-label, multicenter Phase 1 study of AQUA07 alone and in combination with lorlatinib in advanced or metastatic ALK-positive NSCLC. Separate dose-escalation…
NCT07617337 First-in-human - New trial Spotlight
Prostate cancer
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement
Janux Therapeutics’ first-in-human Phase 1, open-label, multicenter study evaluates JANX013 plus JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a PSMA-directed,…
NCT07813637 First-in-human - New trial
Prostate cancer
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer
This Phase 2, open-label, multicenter, single-arm study tests once-daily oral JNJ-101556143, previously called HLD-0915, in metastatic androgen pathway modulation-resistant prostate cancer. The primary activity…
NCT07832292 Exploratory - New trial
Brain and CNS tumors
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma
University of Minnesota investigators are running REMIND as a small, single-center feasibility study of an additional low-dose radiation treatment after standard upfront treatment for newly diagnosed glioblastoma.…
NCT07831772 Exploratory - New trial
Brain and CNS tumors
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors
This open-label Phase 1 study from Children’s National Research Institute tests neuronavigation-guided low-intensity focused ultrasound with sulfur hexafluoride microbubbles (Lumason, Bracco) to transiently open the…
NCT07664176 Exploratory - New trial
Brain and CNS tumors
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma
This prospective, open-label Phase 2 study from Inova Health Care Services evaluates a three-drug repurposed regimen in recurrent malignant glioma. Valproic acid has histone deacetylase-inhibitory and antiseizure…
NCT07831369 Exploratory - New trial
Brain and CNS tumors
Phase 3 NRG-CC017 tests pulsed radiation plus temozolomide to preserve cognition in glioblastoma
NRG Oncology’s randomized Phase 3 NRG-CC017 trial compares temporally modulated pulsed radiation therapy (TMPRT) with standard external-beam radiation in newly diagnosed, IDH-wildtype, MGMT-unmethylated glioblastoma.…
NCT07452458 Registrational - New trial
Brain and CNS tumors
Phase 1b NEO100 intranasal perillyl alcohol evaluates safety and drug exposure in selected pediatric brain tumors
NeOnc Technologies’ Phase 1b study evaluates intranasal NEO100, a highly purified formulation of perillyl alcohol, in patients aged 5-18 with protocol-defined pediatric high-grade gliomas and selected other malignant…
NCT06357377 Exploratory - New trial Spotlight
Ovarian cancer
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer
AstraZeneca’s TREVI-OC-02 is a randomized, open-label Phase 3 trial comparing torvutatug samrotecan (torvu-sam) plus bevacizumab with bevacizumab alone as first-line maintenance. Torvu-sam is a folate receptor alpha…
NCT07851025 Registrational - New trial
Ovarian cancer
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression
This randomized Phase 2 NCI/NRG Oncology study tests sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) plus bevacizumab against carboplatin and pegylated liposomal doxorubicin, or protocol-allowed gemcitabine,…
NCT07504588 Exploratory - New trial
Ovarian cancer
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab
Merck Sharp & Dohme is running this randomized, open-label Phase 3 study of raludotatug deruxtecan (R-DXd; MK-5909), a CDH6-directed antibody-drug conjugate developed with Daiichi Sankyo that delivers a topoisomerase…
NCT07776691 Registrational - New trial
Breast cancer
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer
This prospective, single-arm pilot from the Renaissance Institute of Precision Oncology and Radiosurgery tests whether a single fraction of highly conformal stereotactic radiation can serve as definitive local…
NCT07844759 Exploratory - New trial
Breast cancer
Phase 1 letrozole SIE study compares quarterly injectable and daily oral aromatase-inhibitor exposure
ROVI Pharmaceuticals Laboratories is running an open-label, one-sequence pharmacokinetic study comparing a long-acting quarterly injectable letrozole formulation with standard daily oral letrozole. Letrozole inhibits…
NCT07401381 Exploratory - New trial
Pancreatic cancer
Phase 1/2 selumetinib plus trastuzumab deruxtecan targets KRAS-mutant, HER2-expressing pancreatic cancer
This NCI-sponsored Phase 1/2 study combines selumetinib (AZD6244, AstraZeneca), an oral MEK1/2 inhibitor, with trastuzumab deruxtecan (T-DXd, Daiichi Sankyo/AstraZeneca), a HER2-directed antibody-drug conjugate…
NCT07619521 Exploratory - New trial
Pancreatic cancer
Phase 1b/2 avutometinib plus defactinib adds RAF/MEK and FAK inhibition to mFOLFIRINOX in pancreatic cancer
This University of Virginia Phase 1b/2, open-label study adds avutometinib, a RAF/MEK pathway inhibitor often described as a RAF/MEK clamp, and defactinib, a focal adhesion kinase inhibitor, to modified FOLFIRINOX in…
NCT07824960 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 toripalimab induction and post-chemoradiation treatment targets locally advanced esophageal squamous cancer
Vanderbilt-Ingram Cancer Center is running this Phase 2 window-of-opportunity study in treatment-naive, resectable stage II-IVA esophageal squamous cell carcinoma. Participants receive induction toripalimab, a…
NCT07836049 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase 3 ASP2138 CLDN18.2×CD3 T-cell engager adds to first-line treatment for gastric and GEJ cancer
Astellas Pharma Global Development is running this randomized, double-blind Phase 3 study in locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction…
NCT07673887 Registrational - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 DAYBreak CLL-306 compares bexobrutideg BTK degradation with pirtobrutinib after covalent BTK inhibition
Nurix Therapeutics’ randomized, open-label, multicenter DAYBreak CLL-306 study compares bexobrutideg (NX-5948), a small-molecule Bruton tyrosine kinase protein degrader, with pirtobrutinib, Eli Lilly’s noncovalent…
NCT07516093 Registrational - New trial
Chronic lymphocytic leukemia
Phase 2 epcoritamab CD3×CD20 consolidation seeks deeper remissions after at least 6 months of BTK inhibition in high-risk CLL
This Phase 2, single-arm, open-label UC Irvine study evaluates epcoritamab consolidation in chronic lymphocytic leukemia with residual disease while receiving a Bruton tyrosine kinase inhibitor (BTKi). Epcoritamab,…
NCT07819214 Exploratory - New trial
Kidney cancer
Phase 1 BMS-986527 allogeneic CD70 CAR T-cell therapy is tested alone or with nivolumab or cabozantinib in clear cell RCC
This Phase 1, multicenter, open-label study from Juno Therapeutics, a Bristol Myers Squibb company, evaluates BMS-986527, a healthy-donor-derived, allogeneic CD70-targeted CAR T-cell therapy in unresectable or…
NCT07848295 First-in-human - New trial
Small cell lung cancer
Phase 3 BrenDeLL-Lung01 tests DLL3-targeted BL-M14D1 plus atezolizumab in first-line extensive-stage SCLC
SystImmune is running this global, open-label, randomized Phase 3 trial in previously untreated extensive-stage small-cell lung cancer. BL-M14D1 is a DLL3-directed antibody-drug conjugate with a topoisomerase I…
NCT07625644 Registrational - New trial
Bladder and urothelial cancer
Phase 2 FORAY tests selective FGFR3 inhibition with vepugratinib in low-grade bladder and upper tract urothelial tumors
FORAY is an Eli Lilly/Loxo Oncology Phase 2, randomized, open-label study of oral vepugratinib (LOXO-435; LY3866288), an isoform-selective FGFR3 tyrosine kinase inhibitor. Its two disease settings are low-grade,…
NCT07827612 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.